Format

Send to

Choose Destination
Oncoimmunology. 2017 Nov 6;7(2):e1387706. doi: 10.1080/2162402X.2017.1387706. eCollection 2018.

Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma.

Author information

1
Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy.
2
Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, 'G. Pascale Tumor National Institute' - Naples, Naples, Italy.
3
Department of basic Medical Sciences, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.

Abstract

Immunotherapy is effective in metastatic melanoma (MM) but most studies failed in discovering a biomarker predictive of clinical response. Exosomes (Exo) from melanoma cells are detectable in sera of MM patients similarly to those produced by immune cells that control the tumor progression. Here, we investigated by flow-cytometry the levels of Exo from both T-cells and dendritic cells (DCs) in 59 patients with MM treated with IPI and the relative expression of PD-1, CD28 and ICOS as well as CD80 and CD86. We found a significant increment of PD-1 and CD28 expression in patients achieving a clinical response reflected by improvement of both PFS and OS. Furthermore, MM patients receiving IPI who showed extended PFS underwent increased expression of CD80 and CD86 on DC-derived Exo at the end of treatment. These results suggest a possible association of both PD-1 and CD28 up-regulation on immune cell-derived Exo in patients with better clinical response to IPI.

KEYWORDS:

CD28; Exosomes; Melanoma; PD1; T-cells

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center